πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,413 results for β€œACE” Clear

  1. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis

    phase 2 small molecule completed

    1 trial
  2. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Cholestatic Liver Disease

    phase 2 small molecule completed

    1 trial
  3. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Biliary Atresia

    phase 2 small molecule completed

    1 trial
  4. Match Placebo to Test Product, SAR441566, SAR441566

    Sanofi-aventis Healthcare Pty Ltd

    Psoriasis

    phase 2 small molecule active

    1 trial
  5. Match placebo to test product, Balinatunfib

    Sanofi-aventis Healthcare Pty Ltd

    Crohn's disease

    phase 2 small molecule active

    1 trial
  6. Match placebo to test product, METHOTREXATE , SAR441566, SAR441566

    Sanofi-aventis Healthcare Pty Ltd

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial
  7. Matched Placebo

    Novo Nordisk A/S

    Mechanical allodynia

    phase 2 small molecule active

    1 trial
  8. Matched Placebo for test product Frexalimab, Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  9. Matched placebo for product, GADOBUTROL , SAR443820

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 2 small molecule active

    1 trial
  10. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial
  11. Matched placebo for test product, SAR444336

    Sanofi-aventis Healthcare Pty Ltd

    Digestive system diseases

    phase 2 small molecule active

    1 trial
  12. Matching Placebo

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial
  13. Matching Placebo for Test, SAR443765 / LUNSEKIMIG

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial
  14. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial
  15. Matching film-coated placebo tablet

    Bioprojet Pharma

    Obsessive compulsive disorder

    phase 2 small molecule active

    1 trial
  16. Matching orodispersible placebo tablet

    Bioprojet Pharma

    Eosinophilic esophagitis

    phase 2 small molecule active

    1 trial
  17. Matching placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Familial Dysautonomia

    phase 2 small molecule active

    1 trial
  18. Matching placebo for Survodutide, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial
  19. Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial
  20. Mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    COVID-19

    phase 2 small molecule completed

    3 trials
  21. Medtronic PrimeADVANCED Neurostimulator

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 2 other completed

    1 trial
  22. Merimepodib

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  23. Midostaurin

    Novartis Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial
  24. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources